Takeda Reports Better Version Of Prevacid Heartburn Drug
This article was originally published in PharmAsia News
Executive Summary
In a comparison with its best-selling drug Prevacid (lansoprazole), Takeda Pharmaceutical says its new version of the heartburn drug, TAK-390MR, has proven to be more effective. Takeda said a pair of Phase III trials of patients with erosive esophagitis showed the newer version to be better. The results are important to Takeda since Prevacid is set to lose patent protection in November of next year. Takeda hopes to introduce the new version by the end of this year. (Click here for more
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.